Domperidone is a dopamine blocker and an antidopaminergic reagent.Target: Dopamine ReceptorDomperidone is a useful alternative to metoclopramide for treatment of gastroparesis due to better tolerability. Effectiveness and side-effects from domperidone may be influenced by patient-related factors including polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, and domperidone targets [1]. Domperidone is a dopamine D(2) receptor antagonist, which has been used as antiemetic agent in human beings. The percentage recovery of domperidone from wastewater was 95.0%. Celiprolol was used as the internal standard to access the percentage extraction of domperidone from wastewater [2]. Domperidone, a dopamine antagonist that does not easily cross the blood-brain barrier, is considered the gold standard for treating gastrointestinal symptoms in patients with Parkinson's disease (PD) because the risk of developing extrapyramidal adverse effects is considered minimal [3].

References:
[1]. Parkman, H.P., et al., Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci, 2011. 56(1): p. 115-24.
[2]. Ali, I., et al., Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta, 2006. 68(3): p. 928-31.
[3]. Lertxundi, U., et al., Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard. Curr Drug Saf, 2013. 8(1): p. 63-8.